SUPPLEMENTARY METHODS

Baseline SARS-CoV-2 testing, individual samples – Example of calculations

Following is an example employer that had 1000 employees (NE) isolating before implementing an employee screening program to return to work. The pre-test prevalence of COVID-19 is 0.5%. The employer implements a screening program testing for SARS-CoV-2 with test sensitivity and specificity of 80% and 99.5%. The number of infected and "healthy" (uninfected) employees is unknown but one can calculate the expected number for each based on estimated prevalence, 0.5% (0.005). The expected number of infected versus healthy employees is calculated as:

- Number infected (NI) = NE×prev = 1000×0.005 = 5
- Number healthy (NH) = NE×(1–prev) = 1000×0.995 = 995

Most employees are expected to be healthy since the prevalence is very small. If the 1000 employees are tested using a test with sensitivity = 80% (0.8) and specificity =99.5% (0.995) then the expected number of TP, FP, FN, and TN results (Table 5) are calculated using the formulas from Supplementary Table 1 and presented using the format of Supplementary Table 2.

- TP = number infected × sens = 5×0.80 = 4
- FN = number infected × (1–sens) = 5×0.20 = 1
- TN = number healthy × spec = 995×0.995 = 990
- FP = number healthy × (1–spec) = 995×0.005 = 5

In practice, the employer will not know who is infected versus healthy so they will not know the number of TP, FP, FN, and TN. They will know the number of test positives versus test negatives employees. When prevalence is very low, the number and percent of test positives will be very low and the number and percent of test negatives will be high, calculated as:

- npos=number of test positives = TP+FP = 4+5 = 9
 - Percent of test positives = Number of test positives/number of employees =
 9/1000 or 0.9%
- nneg=number of test negatives = FN+TN = 1+990 = 991
 - Percent of test positives = Number of test positives/number of employees = 991/1000 or 99.1%

It is important to note that the test positive rate (npos/NE) is not the same as prevalence (NI/NE). The test positive rate is lower than prevalence when prevalence is very low and higher than prevalence when prevalence is higher.

While the employer and employee will not know who is infected, knowing the test results informs the employee about the chance they are infected. The pretest probability that an employee is infected is 0.5% (prevalence). The posttest chance they are infected depends on the test result. The chance that a test negative employee is infected (prevalence in test negatives) and the chance that a test positive employee is infected (prevalence in test positives) are calculated using the formulas below. If an employee is test negative, there is a small chance (0.1%) they are infected; if they are test positive, there is a 44.6% chance they are infected.

chance that a test negative employee is infected (1–NPV)

1- (1-prev)×spec/[(1-prev) ×spec + prev× (1-sens)]

= 1- (0.995×0.995)/(0.995×0.995 + 0.005×0.2) = 0.001 or 0.1%

- chance that a test positive employee is infected (PPV)
 - o prev×sens/[prev×sens + (1-prev)×(1-spec)]

= (0.005×0.8)/(0.005×0.8 + 0.995×0.005) = 0.446 or 44.6%

Often literature refers to false negative or false positive *rates*. It is important to clarify the group (denominator) for which this rate is calculated. In the example above, the number of false positive results is 5. The false positive rate can be calculated among different groups, for example

- among all employees: 0.5% (5/1000)
- among healthy employees (1–spec): 0.5% (5/995)
- among test positive employees (1–PPV): 56% (5/9)

Similarly, the false negative "rate" can be calculated among different groups, for example

- among all employees: 0.1% (1/1000)
- among infected employees (1–sens): 20% (1/5)
- among test negative employees (NPV): 0.1% (1/991)

Baseline SARS-CoV-2 testing - pooled samples

The risk of having any infected employee on site using the 1-stage and 2-stage pooled sample approach is calculated by simulation assuming individual outcomes are independent Bernoulli trials. Ten thousand simulated populations of size NE were generated. For each simulated population, the number of FN, FP, TN and TP results across individual declared results were calculated along with an indicator variable if FN>0. The reported expected number of results in Supplementary Tables 8 and 9 were calculated as average values across all simulated populations.

In each single simulated population of size NE, an individual true status and an individual declared test result based on the pooled testing scheme (1-stage and 2-stage) was generated. An individual test result is called 'declared' because it may be an assigned test result based on a pooled test result as opposed to an outcome from an individual level test. First, the individual true status is assigned as infected with probability P. Next, the NE simulated individuals are assigned to a pool of size k. There will be NE/k sample pools. True pool status is assigned as infected if any [at least one] simulated individual in the pool has a true individual status of infected. For pools assigned healthy, the pooled test result is assigned as negative with probability pool specificity (sp.k); for pools assigned infected, the pooled test result is assigned as positive with probability pool sensitivity (se.k). The stage 1 individual test result is assigned the pooled test result. The stage 2 individual test result is assigned the pooled test result when the pooled test result is negative. If the pooled test result is positive, the stage 2 individual test result is assigned based on the individual true status: if the individual true status is infected then the stage 2 individual test result is assigned positive with probability [individual] sensitivity (se); if the individual true individual status is healthy then the stage 2 individual test result is assigned negative with probability [individual] specificity (sp).

Summary results from the simulation are reported in Supplementary Tables 8 and 9. In some simulated populations when prevalence is low, there were no declared positive individual result generated. Therefore, the average number of positive declared individual results and FP declared individual results were calculated conditional on at least one positive declared individual result in the simulated population. The percent of time there was no declared positive individual result generated across all simulated populations is reported in the last column of each table.

Supplementary Table 1. Formulas

No.	Formula Name	Formula Description/Notes	Formula
1	No Testing –	Calculated based on modeling the number of	Pr(Z≥1) = 1 – [Pr(Z=0)]
	Probability of at	infected individuals out of NE as following a	$= 1 - (1 - P)^{NE}$
	least one infected	binomial distribution with parameters NE and P.	
		Z=number infected out of NE.	
2	Cross tabulation	Expected counts are calculated based on modeling	NI = NE × P
	expected test	the number of test positive employees out of NI	$NH = NE \times (1 - P)$
	results vs true	infected individuals as following a binomial	$TP = NI \times se = NE \times P \times se$
	status	distribution with parameters NI and sensitivity.	$FN = NI \times (1 - se) = NE \times P \times (1 - se)$
		and the number of test negative employees out of	$FP = NH \times (1 - sp) = NE \times (1 - P) \times (1 - sp)$
		NH uninfected individuals as following a binomial	$TN = NH \times sp = NE \times (1 - P) \times sp$
		distribution with parameters NH and specificity.	Npos = TP + FP = NE \times P \times se + NE \times (1- P) \times (1- sp)
		P, se, and sp are represented as decimals between	Nneg = FN + TN = NE \times P \times (1- se) + NE \times (1- P) \times sp
		0 and 1.	
3	Negative predictive	Likelihood of a screen negative employee being	$NPV=(1-P)\times sp/[(1-P)\times sp + P\times(1-se)]$
	value (NPV)	uninfected. P, se, and sp are represented as	
		decimals between 0 and 1.	
		Likelihood of a screen negative employee being	1-NPV
		infected.	
4	Positive predictive	Likelihood of a screen positive employee being	PPV=P×se/[P×se + (1–P)×(1–sp)]
	value (PPV)	infected. P, se, and sp are represented as decimals	
		between 0 and 1.	
		Likelihood of a screen positive employee being	1-PPV
		uninfected.	
5	Baseline screen,	The risk of having any infected employee on site is	$Pr(Z \ge 1) = 1 - [Pr(Z = 0)]$
	individual samples	the probability of having at least 1 false negative	$= 1 - [1 - (1 - NPV)^{Nneg}]$
	 Probability of at 	employee out of Nneg test negative employees on	$= 1 - NPV^{Nneg}$
	least one infected	site. Calculated by modeling the number of	
		infected [FN] individuals out of Nneg test negative	

No.	Formula Name	Formula Description/Notes	Formula
		employees as following a binomial distribution	
		with parameters Nneg and 1–NPV, where Nneg is	
		treated as a known quantity. Z=number infected	
		out of Nneg.	
6	Sample pooling -	Test sensitivity for pooled sample was estimated	se.5 = se – 0.015
	sensitivity	as sensitivity for individual samples minus 1.5%	
		and 2.5% for k=5 and 10, respectively. Se is	se.10 = se – 0.025
		represented as a decimal between 0 and 1.	
7	Sample pooling –	The prevalence of infected pools is the pre-test	$Pr(Z \ge 1) = 1 - [Pr(Z = 0)] = 1 - (1 - P)^{k}$
	prevalence of	probability that a pool is infected. A pool is	
	infected pools	infected if at least 1 sample in the pool is from an	
		infected employee. The probability that a pool is	
		infected is calculated by modeling the number of	
		infected samples out of k samples in the pool as	
		following a binomial distribution with parameters	
		k and individual pre-test prevalence P. Z=number	
		infected samples out of k.	
8	Expected number	The expected number of days an infected	TC = (TA) se + (TA+TI)(1–se)se + (TA+2TI)(1–se) ² se +
	of days an infected	employee will be on site before being detected	····+ (TA+(m –1)TI)(1–se) ^{m-1} se + TINF(1–se) ^m
	employee on site	(TC) depends on se, the test interval (TI) and	
		turnaround time (TA). m is the number of tests per	m = 1 + integer part of ((TINF-1)/TI)
		infected and contagious time	

Supplementary Table 2. Cross tabulation of expected SARS-CoV-2 Test Result versus the true status

		True S		
		Infected	Uninfected "Healthy"	Total
Tost Rosult	Test Positive	ТР	FP	Npos
lest Result	Test Negative	FN	TN	Nneg
	Total	NI	NH	NE

Based on employees tested (NE), prevalence (P), test sensitivity, and test specificity. FN, false negative; FP, false positive; NH, number of "healthy" employees, where healthy means uninfected with respect to SARS-CoV-2; NI, number of infected employees out of NE screened at point in time; Npos, number of test positive employees; Nneg, number of test negative employees; TN, true negative; TP, true positive. Supplementary Table 3. Probability an infected employee on site will be detected by each

test on site

	Probability calculation
By Test 1	se
By Test 2	se + se(1-se)
By Test 3	se + se(1-se) + se(1-se) ²
By Test 4	se + se(1-se) + se(1-se) ² + se(1-se) ³
By Test m	se + se(1-se) + se(1-se) ² + + se(1-se) ^{m-1}

m, number of times individual tested per time infected; se, sensitivity of test.

				Bas	eline Scree	ening Test:	70% sen	sitivity, 99.5%	6 specificit	У	
		No So	reen	Scree	n negative	s out of NI		Screen positives out of NE			
					"return to	work"		"isolate/stay home"			
	Group	Number	Proh at	Prevalence			Prob.	Prevalence			
Pre-test	Sizo		OVID19 least 1	in screen	Number	Number	at	in screen	Number	Number	
Prevalence	NE	Infactod	infacted	negatives,	TN	FN	least	positives,	ТР	FP	
	INE	mected	mected	1 – NPV			1 FN	PPV			
0.001%	20	0.0	0.02%	0.000%	19.9	0.0	0.0%	0.1%	0.0	0.1	
	50	0.0	0.05%	0.000%	49.7	0.0	0.0%	0.1%	0.0	0.2	
	100	0.0	0.10%	0.000%	99.5	0.0	0.0%	0.1%	0.0	0.5	
	250	0.0	0.25%	0.000%	248.7	0.0	0.1%	0.1%	0.0	1.2	
	500	0.0	0.50%	0.000%	497.5	0.0	0.1%	0.1%	0.0	2.5	
	1000	0.0	1.00%	0.000%	995.0	0.0	0.3%	0.1%	0.0	5.0	
0.010%	20	0.0	0.20%	0.003%	19.9	0.0	0.1%	1.4%	0.0	0.1	
	50	0.0	0.50%	0.003%	49.7	0.0	0.1%	1.4%	0.0	0.2	
	100	0.0	1.00%	0.003%	99.5	0.0	0.3%	1.4%	0.0	0.5	
	250	0.0	2.47%	0.003%	248.7	0.0	0.7%	1.4%	0.0	1.2	
	500	0.0	4.88%	0.003%	497.5	0.0	1.5%	1.4%	0.0	2.5	
	1000	0.1	9.52%	0.003%	994.9	0.0	3.0%	1.4%	0.1	5.0	
0.100%	20	0.0	1.98%	0.030%	19.9	0.0	0.6%	12.3%	0.0	0.1	
	50	0.0	4.88%	0.030%	49.7	0.0	1.5%	12.3%	0.0	0.2	
	100	0.1	9.52%	0.030%	99.4	0.0	3.0%	12.3%	0.1	0.5	
	250	0.2	22.13%	0.030%	248.5	0.1	7.2%	12.3%	0.2	1.2	
	500	0.5	39.36%	0.030%	497.0	0.2	13.9%	12.3%	0.4	2.5	
	1000	1.0	63.23%	0.030%	994.0	0.3	25.9%	12.3%	0.7	5.0	

Supplementary Table 4. Risk comparison between no screening and baseline screen with a 70% sensitivity and 99.5% specificity

				Baseline Screening Test: 70% sensitivity, 99.5% spec						у
		No So	reen	Scree	n negative	s out of NI	-	Screen positives out of NE		
					return to	work"		"isolat	e/stay hoi	me"
Pre-test Prevalence	Group Size	Number COVID19	Prob. at least 1	Prevalence in screen negatives.	Number TN	Number FN	Prob. at least	Prevalence in screen positives.	Number TP	Number FP
	NE	Infected	infected	1 – NPV			1 FN	PPV		
0.500%	20	0.1	9.54%	0.151%	19.8	0.0	3.0%	41.3%	0.1	0.1
	50	0.2	22.17%	0.151%	49.5	0.1	7.2%	41.3%	0.2	0.2
	100	0.5	39.42%	0.151%	99.0	0.2	13.9%	41.3%	0.4	0.5
	250	1.2	71.44%	0.151%	247.5	0.4	31.3%	41.3%	0.9	1.2
	500	2.5	91.84%	0.151%	495.0	0.8	52.8%	41.3%	1.8	2.5
	1000	5.0	99.33%	0.151%	990.0	1.5	77.7%	41.3%	3.5	5.0
1.000%	20	0.2	18.21%	0.304%	19.7	0.1	5.8%	58.6%	0.1	0.1
	50	0.5	39.50%	0.304%	49.3	0.2	14.0%	58.6%	0.4	0.2
	100	1.0	63.40%	0.304%	98.5	0.3	26.0%	58.6%	0.7	0.5
	250	2.5	91.89%	0.304%	246.3	0.8	52.8%	58.6%	1.8	1.2
	500	5.0	99.34%	0.304%	492.5	1.5	77.7%	58.6%	3.5	2.5
	1000	10.0	100.00%	0.304%	985.0	3.0	95.0%	58.6%	7.0	5.0
2.000%	20	0.4	33.24%	0.612%	19.5	0.1	11.3%	74.1%	0.3	0.1
	50	1.0	63.58%	0.612%	48.8	0.3	26.0%	74.1%	0.7	0.2
	100	2.0	86.74%	0.612%	97.5	0.6	45.2%	74.1%	1.4	0.5
	250	5.0	99.36%	0.612%	243.8	1.5	77.8%	74.1%	3.5	1.2
	500	10.0	100.00%	0.612%	487.6	3.0	95.1%	74.1%	7.0	2.5
	1000	20.0	100.00%	0.612%	975.1	6.0	99.8%	74.1%	14.0	4.9

FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; prob, probability; TN, true negative; TP, true positive.

				Base	eline Scree	ening Test:	80% sen	sitivity, 99.5%	6 specificit	у
		No So	reen	Scree	n negative	s out of NI		Screen po	ositives ou	t of NE
					"return to	work"	"isolate/stay home"			
	Group	Number	Proh at	Prevalence			Prob.	Prevalence		
Pre-test	Sizo		OVID19 least 1	in screen	Number	Number	at	in screen	Number	Number
Prevalence	NE	Infected	infocted	negatives,	TN	FN	least	positives,	ТР	FP
	INL	intecteu	intected	1 – NPV			1 FN	PPV		
0.001%	20	0.0	0.02%	0.000%	19.9	0.0	0.0%	0.2%	0.0	0.1
	50	0.0	0.05%	0.000%	49.7	0.0	0.0%	0.2%	0.0	0.2
	100	0.0	0.10%	0.000%	99.5	0.0	0.0%	0.2%	0.0	0.5
	250	0.0	0.25%	0.000%	248.7	0.0	0.0%	0.2%	0.0	1.2
	500	0.0	0.50%	0.000%	497.5	0.0	0.1%	0.2%	0.0	2.5
	1000	0.0	1.00%	0.000%	995.0	0.0	0.2%	0.2%	0.0	5.0
0.010%	20	0.0	0.20%	0.002%	19.9	0.0	0.0%	1.6%	0.0	0.1
	50	0.0	0.50%	0.002%	49.7	0.0	0.1%	1.6%	0.0	0.2
	100	0.0	1.00%	0.002%	99.5	0.0	0.2%	1.6%	0.0	0.5
	250	0.0	2.47%	0.002%	248.7	0.0	0.5%	1.6%	0.0	1.2
	500	0.0	4.88%	0.002%	497.5	0.0	1.0%	1.6%	0.0	2.5
	1000	0.1	9.52%	0.002%	994.9	0.0	2.0%	1.6%	0.1	5.0
0.100%	20	0.0	1.98%	0.020%	19.9	0.0	0.4%	13.8%	0.0	0.1
	50	0.0	4.88%	0.020%	49.7	0.0	1.0%	13.8%	0.0	0.2
	100	0.1	9.52%	0.020%	99.4	0.0	2.0%	13.8%	0.1	0.5
	250	0.2	22.13%	0.020%	248.5	0.0	4.9%	13.8%	0.2	1.2
	500	0.5	39.36%	0.020%	497.0	0.1	9.5%	13.8%	0.4	2.5
	1000	1.0	63.23%	0.020%	994.0	0.2	18.1%	13.8%	0.8	5.0

Supplementary Table 5. Risk comparison between no screening and baseline screen with an 80% sensitivity and 99.5% specificity

				Bas	eline Scree	ning Test:	80% sen	sitivity, 99.5%	% specificit	у		
		No So	reen	Scree	n negative	s out of NI		Screen po	Screen positives out of NE			
					return to	work"		"isolate/stay home"				
Pre-test Prevalence	Group Size NE	Number COVID19 Infected	Prob. at least 1 infected	Prevalence in screen negatives, 1 – NPV	Number TN	Number FN	Prob. at least 1 FN	Prevalence in screen positives, PPV	Number TP	Number FP		
0.500%	20	0.1	9.54%	0.101%	19.8	0.0	2.0%	44.6%	0.1	0.1		
	50	0.2	22.17%	0.101%	49.5	0.0	4.9%	44.6%	0.2	0.2		
	100	0.5	39.42%	0.101%	99.0	0.1	9.5%	44.6%	0.4	0.5		
	250	1.2	71.44%	0.101%	247.5	0.2	22.1%	44.6%	1.0	1.2		
	500	2.5	91.84%	0.101%	495.0	0.5	39.4%	44.6%	2.0	2.5		
	1000	5.0	99.33%	0.101%	990.0	1.0	63.2%	44.6%	4.0	5.0		
1.000%	20	0.2	18.21%	0.203%	19.7	0.0	3.9%	61.8%	0.2	0.1		
	50	0.5	39.50%	0.203%	49.3	0.1	9.5%	61.8%	0.4	0.2		
	100	1.0	63.40%	0.203%	98.5	0.2	18.1%	61.8%	0.8	0.5		
	250	2.5	91.89%	0.203%	246.3	0.5	39.4%	61.8%	2.0	1.2		
	500	5.0	99.34%	0.203%	492.5	1.0	63.2%	61.8%	4.0	2.5		
	1000	10.0	100.00%	0.203%	985.0	2.0	86.5%	61.8%	8.0	5.0		
2.000%	20	0.4	33.24%	0.409%	19.5	0.1	7.7%	76.6%	0.3	0.1		
	50	1.0	63.58%	0.409%	48.8	0.2	18.2%	76.6%	0.8	0.2		
	100	2.0	86.74%	0.409%	97.5	0.4	33.0%	76.6%	1.6	0.5		
	250	5.0	99.36%	0.409%	243.8	1.0	63.3%	76.6%	4.0	1.2		
	500	10.0	100.00%	0.409%	487.6	2.0	86.5%	76.6%	8.0	2.5		
	1000	20.0	100.00%	0.409%	975.1	4.0	98.2%	76.6%	16.0	4.9		

FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; prob, probability; TN, true negative; TP, true positive.

				Bas	eline Scree	ening Test:	90% sen	sitivity, 99.5%	6 specificit	У	
		No So	reen	Scree	n negative	s out of NE		Screen po	ositives ou	t of NE	
					"return to	work"		"isolate/stay home"			
	Group	Number	Proh at	Prevalence			Prob.	Prevalence			
Pre-test	Sizo		COVID19 least 1	in screen	Number	Number	at	in screen	Number	Number	
Prevalence	NE	Infected	infocted	negatives,	TN	FN	least	positives,	ТР	FP	
	INL	intecteu	intected	1 – NPV			1 FN	PPV			
0.001%	20	0.0	0.02%	0.000%	19.9	0.0	0.0%	0.2%	0.0	0.1	
	50	0.0	0.05%	0.000%	49.7	0.0	0.0%	0.2%	0.0	0.2	
	100	0.0	0.10%	0.000%	99.5	0.0	0.0%	0.2%	0.0	0.5	
	250	0.0	0.25%	0.000%	248.7	0.0	0.0%	0.2%	0.0	1.2	
	500	0.0	0.50%	0.000%	497.5	0.0	0.0%	0.2%	0.0	2.5	
	1000	0.0	1.00%	0.000%	995.0	0.0	0.1%	0.2%	0.0	5.0	
0.010%	20	0.0	0.20%	0.001%	19.9	0.0	0.0%	1.8%	0.0	0.1	
	50	0.0	0.50%	0.001%	49.7	0.0	0.0%	1.8%	0.0	0.2	
	100	0.0	1.00%	0.001%	99.5	0.0	0.1%	1.8%	0.0	0.5	
	250	0.0	2.47%	0.001%	248.7	0.0	0.2%	1.8%	0.0	1.2	
	500	0.0	4.88%	0.001%	497.5	0.0	0.5%	1.8%	0.0	2.5	
	1000	0.1	9.52%	0.001%	994.9	0.0	1.0%	1.8%	0.1	5.0	
0.100%	20	0.0	1.98%	0.010%	19.9	0.0	0.2%	15.3%	0.0	0.1	
	50	0.0	4.88%	0.010%	49.7	0.0	0.5%	15.3%	0.0	0.2	
	100	0.1	9.52%	0.010%	99.4	0.0	1.0%	15.3%	0.1	0.5	
	250	0.2	22.13%	0.010%	248.5	0.0	2.5%	15.3%	0.2	1.2	
	500	0.5	39.36%	0.010%	497.0	0.0	4.9%	15.3%	0.4	2.5	
	1000	1.0	63.23%	0.010%	994.0	0.1	9.5%	15.3%	0.9	5.0	

Supplementary Table 6. Risk comparison between no screening and baseline screen with a 90% sensitivity and 99.5% specificity

				Bas	Baseline Screening Test: 90% sensitivity, 99.5% specificity								
		No So	reen	Scree	n negative	s out of NI		Screen positives out of NE					
				"return to work"				"isolate/stay home"					
Pre-test Prevalence	Group Size NE	Number COVID19 Infected	Prob. at least 1 infected	Prevalence in screen negatives, 1 – NPV	Number TN	Number FN	Prob. at least 1 FN	Prevalence in screen positives, PPV	Number TP	Number FP			
0.500%	20	0.1	9.54%	0.050%	19.8	0.0	1.0%	47.5%	0.1	0.1			
	50	0.2	22.17%	0.050%	49.5	0.0	2.5%	47.5%	0.2	0.2			
	100	0.5	39.42%	0.050%	99.0	0.0	4.9%	47.5%	0.4	0.5			
	250	1.2	71.44%	0.050%	247.5	0.1	11.8%	47.5%	1.1	1.2			
	500	2.5	91.84%	0.050%	495.0	0.2	22.1%	47.5%	2.2	2.5			
	1000	5.0	99.33%	0.050%	990.0	0.5	39.4%	47.5%	4.5	5.0			
1.000%	20	0.2	18.21%	0.101%	19.7	0.0	2.0%	64.5%	0.2	0.1			
	50	0.5	39.50%	0.101%	49.3	0.0	4.9%	64.5%	0.4	0.2			
	100	1.0	63.40%	0.101%	98.5	0.1	9.5%	64.5%	0.9	0.5			
	250	2.5	91.89%	0.101%	246.3	0.2	22.1%	64.5%	2.2	1.2			
	500	5.0	99.34%	0.101%	492.5	0.5	39.4%	64.5%	4.5	2.5			
	1000	10.0	100.00%	0.101%	985.0	1.0	63.2%	64.5%	9.0	5.0			
2.000%	20	0.4	33.24%	0.205%	19.5	0.0	3.9%	78.6%	0.4	0.1			
	50	1.0	63.58%	0.205%	48.8	0.1	9.5%	78.6%	0.9	0.2			
	100	2.0	86.74%	0.205%	97.5	0.2	18.1%	78.6%	1.8	0.5			
	250	5.0	99.36%	0.205%	243.8	0.5	39.4%	78.6%	4.5	1.2			
	500	10.0	100.00%	0.205%	487.6	1.0	63.3%	78.6%	9.0	2.5			
	1000	20.0	100.00%	0.205%	975.1	2.0	86.5%	78.6%	18.0	4.9			

FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; prob, probability; TN, true negative; TP, true positive.

				Bas	Baseline Screening Test: 95% sensitivity, 99.5% specificity								
		No So	creen	Scree	n negative 'return to	s out of NE work"	Screen po "isolat	Screen positives out of NE "isolate/stay home"					
Pre-test	Group	Number	Prob. at	Prevalence in screen	Number	Number	Prob. at	Prevalence in screen	Number	Number			
Prevalence	NE	Infected	infected	negatives, 1 – NPV	TN	FN	least 1 FN	positives, PPV	ТР	FP			
0.001%	20	0.0	0.02%	0.000%	19.9	0.0	0.0%	0.2%	0.0	0.1			
	50	0.0	0.05%	0.000%	49.7	0.0	0.0%	0.2%	0.0	0.2			
	100	0.0	0.10%	0.000%	99.5	0.0	0.0%	0.2%	0.0	0.5			
	250	0.0	0.25%	0.000%	248.7	0.0	0.0%	0.2%	0.0	1.2			
	500	0.0	0.50%	0.000%	497.5	0.0	0.0%	0.2%	0.0	2.5			
	1000	0.0	1.00%	0.000%	995.0	0.0	0.0%	0.2%	0.0	5.0			
0.010%	20	0.0	0.20%	0.001%	19.9	0.0	0.0%	1.9%	0.0	0.1			
	50	0.0	0.50%	0.001%	49.7	0.0	0.0%	1.9%	0.0	0.2			
	100	0.0	1.00%	0.001%	99.5	0.0	0.0%	1.9%	0.0	0.5			
	250	0.0	2.47%	0.001%	248.7	0.0	0.1%	1.9%	0.0	1.2			
	500	0.0	4.88%	0.001%	497.5	0.0	0.2%	1.9%	0.0	2.5			
	1000	0.1	9.52%	0.001%	994.9	0.0	0.5%	1.9%	0.1	5.0			
0.100%	20	0.0	1.98%	0.005%	19.9	0.0	0.1%	16.0%	0.0	0.1			
	50	0.0	4.88%	0.005%	49.7	0.0	0.2%	16.0%	0.0	0.2			
	100	0.1	9.52%	0.005%	99.4	0.0	0.5%	16.0%	0.1	0.5			
	250	0.2	22.13%	0.005%	248.5	0.0	1.2%	16.0%	0.2	1.2			
	500	0.5	39.36%	0.005%	497.0	0.0	2.5%	16.0%	0.5	2.5			
	1000	1.0	63.23%	0.005%	994.0	0.1	4.9%	16.0%	1.0	5.0			

Supplementary Table 7. Risk comparison between no screening and baseline screen with 95% sensitivity and 99.5% specificity

				Baseline Screening Test: 95% sensitiv					nsitivity, 99.5% specificity			
		No So	reen	Scree	n negative	s out of NI	-	Screen po	ositives ou	t of NE		
					"return to work"			"isolate/stay home"				
Pre-test	Group Size	Number COVID19	Prob. at least 1	Prevalence in screen	Number	Number	Prob. at	Prevalence in screen	Number	Number		
Flevalence	NE	Infected	infected	1 – NPV		FIN	1 FN	PPV	IF	FF		
0.500%	20	0.1	9.54%	0.025%	19.8	0.0	0.5%	48.8%	0.1	0.1		
	50	0.2	22.17%	0.025%	49.5	0.0	1.2%	48.8%	0.2	0.2		
	100	0.5	39.42%	0.025%	99.0	0.0	2.5%	48.8%	0.5	0.5		
	250	1.2	71.44%	0.025%	247.5	0.1	6.1%	48.8%	1.2	1.2		
	500	2.5	91.84%	0.025%	495.0	0.1	11.8%	48.8%	2.4	2.5		
	1000	5.0	99.33%	0.025%	990.0	0.3	22.1%	48.8%	4.8	5.0		
1.000%	20	0.2	18.21%	0.051%	19.7	0.0	1.0%	65.7%	0.2	0.1		
	50	0.5	39.50%	0.051%	49.3	0.0	2.5%	65.7%	0.5	0.2		
	100	1.0	63.40%	0.051%	98.5	0.1	4.9%	65.7%	1.0	0.5		
	250	2.5	91.89%	0.051%	246.3	0.1	11.8%	65.7%	2.4	1.2		
	500	5.0	99.34%	0.051%	492.5	0.3	22.1%	65.7%	4.8	2.5		
	1000	10.0	100.00%	0.051%	985.0	0.5	39.4%	65.7%	9.5	5.0		
2.000%	20	0.4	33.24%	0.102%	19.5	0.0	2.0%	79.5%	0.4	0.1		
	50	1.0	63.58%	0.102%	48.8	0.1	4.9%	79.5%	1.0	0.2		
	100	2.0	86.74%	0.102%	97.5	0.1	9.5%	79.5%	1.9	0.5		
	250	5.0	99.36%	0.102%	243.8	0.3	22.1%	79.5%	4.8	1.2		
	500	10.0	100.00%	0.102%	487.6	0.5	39.4%	79.5%	9.5	2.5		
	1000	20.0	100.00%	0.102%	975.1	1.0	63.2%	79.5%	19.0	4.9		

FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; prob, probability; TN, true negative; TP, true positive.

Supplementary Table 8. Impact of the 1-stage sample pooling approach for pool sizes 5 or 10 versus an individual testing

approach (not pooled) using a test with individual sensitivity of 80% and specificity of 99.5%.

		P	ool Paran	neters	Te	ests	Declared individual results negative out of NE "return to work"				Declared individual results positive out of NE "isolate/stay home"			
Pre-test prev	NE	k	Pool prev	Pool sens	#	%	Prev. in screen neg	TN	FN	Prob at least 1 FN	Prev in screen pos	ТР	FP	% no pos*
0.01%	1000	Not pooled			1000	100%	0.00%	994.9	0.0	1.9%	1.6%	0.1	5.0	1%
	1000	5	0.05%	78.5%	200	20%	0.00%	994.7	0.0	2.1%	1.5%	0.0	5.3	34%
	1000	10	0.10%	77.5%	100	10%	0.00%	994.3	0.0	2.0%	1.3%	0.1	5.6	34%
0.1%	1000	Not pooled		led	1000	100%	0.02%	994.0	0.2	17.7%	13.7%	0.8	5.0	0%
	1000	5	0.50%	78.5%	200	20%	0.02%	990.8	0.2	18.0%	8.9%	0.8	8.2	17%
	1000	10	1.00%	77.5%	100	10%	0.02%	987.0	0.2	19.4%	6.2%	0.8	12.0	17%
1.0%	1000	Not pooled			1000	100%	0.20%	985.0	2.0	86.2%	61.7%	8.0	5.0	0%
	1000	5	4.90%	78.5%	200	20%	0.21%	954.1	2.0	86.1%	18.2%	8.0	35.9	0%
	1000	10	9.56%	77.5%	100	10%	0.23%	917.8	2.2	87.8%	9.9%	7.9	72.1	0%

FN, NE with false negative results; FP, NE with false positive results; k, pool size; Neg, negative; pos, positive; prev, prevalence; prob,

probability; sens, sensitivity; TN, NE with true negative results; TP, NE with true positive results; #, number; %, percent.

*Percentage of simulations with no (zero) positive test results.

The grey shaded rows represent individual sample testing (no pooling). Numbers in the table represent average values across 10,000 sets of simulated values, or what would be observed on average. Actual numbers will vary.

Supplementary Table 9. Impact of the Dorfman 2-stage sample pooling approach for pool sizes 5 or 10 versus an individual testing

approach (not pooled/retested) using a test with individual sensitivity of 80% and specificity of 99.5%.

							Declared	Declared individual results positive out of NE "isolate/stay home"						
		Ρ	ool Parar	neters	Te	ests	out of NE							
												"return t		
Pre-test	NE	k	Pool	Pool	#	%	Prev in	TN	FN	Prob at	Prev in	ТР	FP	% no
prev			prev	sens			screen			least 1	screen			pos*
							neg			FN	pos			
0.01%	1000	Not pooled/retested		1000	100%	0.00%	994.9	0.0	1.9%	1.6%	0.1	5.0	1%	
	1000	5	0.05%	78.5%	205	21%	0.00%	999.9	0.0	3.5%	70.6%	0.1	0.0	91%
	1000	10	0.10%	77.5%	106	11%	0.00%	999.9	0.0	3.5%	69.6%	0.1	0.0	91%
0.1%	1000	Not pooled/retested		1000	100%	0.02%	994.0	0.2	17.7%	13.7%	0.8	5.0	0%	
	1000	5	0.50%	78.5%	209	21%	0.04%	998.9	0.4	29.8%	95.1%	0.7	0.0	51%
	1000	10	1.00%	77.5%	113	11%	0.04%	998.9	0.4	30.6%	93.2%	0.6	0.1	51%
1.0%	1000	Not pooled/retested			1000	100%	0.20%	985.0	2.0	86.2%	61.7%	8.0	5.0	0%
	1000	5	4.90%	78.5%	244	24%	0.36%	989.8	3.6	97.4%	97.6%	6.4	0.2	0%
	1000	10	9.56%	77.5%	180	18%	0.38%	989.6	3.7	97.5%	95.1%	6.3	0.4	0%

FN, NE with false negative results; FP, NE with false positive results; k, pool size; Neg, negative; pos, positive; prev, prevalence; prob,

probability; sens, sensitivity; TN, NE with true negative results; TP, NE with true positive results; #, number; %, percent.

*Percentage of simulations with no (zero) positive test results.

The grey shaded rows represent individual sample testing (no pooling and no retesting). Numbers in the table represent average values across 10,000 sets of simulated values, or what would be observed on average. Actual numbers will vary.

Supplementary Table 10. Expected number of days and percent of 14-day contagious period that an infected contagious

		1-day	/ turnaround	time		2-day turnaround time						
Testing Interval (days)	No. tests per TINF	60% Sens	70% Sens	80% Sens	90% Sens	No. tests per TINF	60% Sens	70% Sens	80% Sens	90% Sens		
1	14	1.7 (12%)	1.4 (10%)	1.2 (9%)	1.1 (8%)							
2	7	2.3 (17%)	1.9 (13%)	1.5 (11%)	1.2 (9%)	7	3.3 (24%)	2.9 (20%)	2.5 (18%)	2.2 (16%)		
4	4	3.5 (25%)	2.7 (19%)	2.0 (14%)	1.4 (10%)	4	4.5 (32%)	3.7 (26%)	3.0 (21%)	2.4 (17%)		
7	2	4.8 (34%)	3.6 (26%)	2.6 (19%)	1.8 (13%)	2	5.6 (40%)	4.6 (33%)	3.6 (26%)	2.8 (20%)		
14	1	6.2 (44%)	4.9 (35%)	3.6 (26%)	2.3 (16%)	1	6.8 (49%)	5.6 (40%)	4.4 (31%)	3.2 (23%)		

employee remains on site until detected as test positive with a 1- or 2-day turnaround time

TINF, time infected, asymptomatic but contagious; sens, sensitivity.

Supplementary Table 11. Expected number of days and percent of 21-day contagious period that an infected contagious

		1-day	/ turnaround	time		2-day turnaround time						
Testing Interval (days)	No. tests per TINF	60% Sens	70% Sens	80% Sens	90% Sens	No. tests per TINF	60% Sens	70% Sens	80% Sens	90% Sens		
1	21	1.7 (8%)	1.4 (7%)	1.2 (6%)	1.1 (5%)							
2	11	2.3 (11%)	1.9 (9%)	1.5 (7%)	1.2 (6%)	11	3.3 (16%)	2.9 (14%)	2.5 (12%)	2.2 (11%)		
4	6	3.6 (17%)	2.7 (13%)	2.0 (10%)	1.4 (7%)	6	4.6 (22%)	3.7 (18%)	3.0 (14%)	2.4 (12%)		
7	3	5.3 (25%)	3.9 (19%)	2.7 (13%)	1.8 (8%)	3	6.2 (30%)	4.9 (23%)	3.7 (18%)	2.8 (13%)		
14	2	7.6 (36%)	5.7 (27%)	4.0 (19%)	2.5 (12%)	2	8.4 (40%)	6.7 (32%)	5.0 (24%)	3.4 (16%)		

employee remains on site until detected as test positive with a 1- or 2-day turnaround time

TINF, time infected, asymptomatic but contagious; sens, sensitivity



Supplementary Figure 1. Formula for calculating the expected number of days an infected

employee will be on site before being detected



TINF = total time contagious (input)

Supplementary Figure 2. Description of testing and timing of results in relation to TA, TI and TINF to calculate the expected number of days an infected employee will be on site before being detected